Inactive Instrument

Cardax, Inc. Stock Other OTC

Biotechnology & Medical Research

Cardax, Inc. is a geroscience company focused on pharmaceutical and nutraceutical applications of astaxanthin. The Company markets ZanthoSyn, an astaxanthin dietary supplement for lifespan and health span (inflammatory health), including joint and muscle function, cognitive performance, and cardiovascular health. ZanthoSyn is available through its commercial Website. ZanthoSyn contains pure astaxanthin prepared by natural product total synthesis. The Company is also advancing CDX-101, its pharmaceutical candidate, for the diseases of aging. CDX-101 is an astaxanthin Rx candidate for cardiovascular inflammation and dyslipidemia. CDX-301 is its zeaxanthin pharmaceutical candidate for macular degeneration. It may seek to monetize its CDX-301 pharmaceutical assets through licensing or sale.

Employees

Sector

Biotechnology & Medical Research

More about the company

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	413K 363K 337K 309K 581K 39.75M 590K 4M 1.56M 19.54M 1.55M 1.52M 67.57M	P/E 2019	-1.36x	P/E 2020	-0.27x
Enterprise Value	5.17M 4.54M 4.23M 3.88M 7.29M 498M 7.4M 50.19M 19.61M 245M 19.43M 19.01M 847M	EV / Sales 2019	13,421,701x	EV / Sales 2020	11,249,008x
Free-Float	69.33%	Yield 2019 *	-	Yield 2020	-

21-09-15	Cardax, Inc. announced a financing transaction	CI
21-08-31	Cardax, Inc. Announces Restructuring of Board of Directors	CI
21-05-14	Cardax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	CI
21-01-10	Cardax, Inc. announced that it expects to receive $10 million in funding from US Capital Global Investment Management, LLC	CI
20-11-17	Cardax, Inc. announced that it expects to receive $10 million in funding	CI
20-11-13	Cardax, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	CI
20-08-14	Cardax, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	CI
20-05-15	Cardax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	CI
20-03-30	Cardax, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	CI
20-03-15	Cardax, Inc. announced that it expects to receive $0.46 million in funding	CI
20-02-03	Cardax, Inc. has Changed its Ticker to CDXI from CDXID	CI
20-01-20	Cardax, Inc. announced that it expects to receive $0.25 million in funding from Harbor Gates Capital, LLC	CI
19-11-14	Cardax, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	CI

21-08-11	CARDAX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
21-08-11	Cardax : Voluntarily Suspends SEC Reporting Obligations	PR
21-07-01	CARDAX, INC. : Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits (form 8-K)	AQ
21-05-14	CARDAX : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
21-05-14	Cardax : Reports Q1 2021 Results	PR

Manager	Title	Age	Since
David G. Watumull CEO	Chief Executive Officer	76	2014-02-06
David Watumull DFI	Director of Finance/CFO	44	2021-07-31
Gilbert Shin SAM	Sales & Marketing	-	2017-10-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CARDAX, INC.	-.--%	-.--%	-	-	0
LONZA GROUP AG	+1.07%	-3.49%	-3.25%	+12.87%	46.35B
REVOLUTION MEDICINES, INC.	+0.25%	+1.65%	+408.41%	+629.49%	40.13B
BEONE MEDICINES AG	-0.27%	+4.45%	+9.93%	+66.92%	36.33B
IQVIA HOLDINGS INC.	+0.35%	+0.87%	+3.60%	-8.81%	34.6B
CELLTRION, INC.	+3.14%	+1.02%	+3.37%	+38.15%	26.77B
MEDPACE HOLDINGS, INC.	-0.73%	+11.84%	+31.97%	+143.53%	16.91B
ASCENDIS PHARMA A/S	+0.47%	-2.74%	-	-	16.66B
EUROFINS SCIENTIFIC SE	+0.42%	-5.52%	+0.76%	+8.50%	13.05B
ICON PUBLIC LIMITED COMPANY	-2.68%	-2.49%	-15.00%	-31.68%	13.05B
Average	+0.20%	+0.99%	+54.97%	+107.37%	27.09B
Weighted average by Cap.	+0.46%	+1.10%	+75.57%	+137.02%

Cardax, Inc. Stock Other OTC

Stocks

Biotechnology & Medical Research

Valuation: Cardax, Inc.

Latest news : Cardax, Inc.

Press Releases: Cardax, Inc.

Managers and Directors: Cardax, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

	2019	2020
Net sales	0.71 0.62 0.58 0.53 1 68.47 1.02 6.9 2.69 33.66 2.67 2.61 116.38	0.54 0.47 0.44 0.4 0.76 51.9 0.77 5.23 2.04 25.52 2.02 1.98 88.22
Net income	-5.09M -4.47M -4.16M -3.82M -7.17M -490M -7.28M -49.4M -19.3M -241M -19.12M -18.71M -834M	-5.06M -4.44M -4.13M -3.79M -7.12M -487M -7.23M -49.03M -19.16M -239M -18.98M -18.57M -828M
Net Debt	2.58M 2.26M 2.1M 1.93M 3.63M 248M 3.68M 24.99M 9.76M 122M 9.67M 9.46M 422M	4.76M 4.18M 3.89M 3.57M 6.71M 459M 6.81M 46.19M 18.04M 225M 17.88M 17.49M 779M